REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
6.87
-0.20 (-2.83%)
Jun 16, 2026, 1:19 PM EDT - Market open
REGENXBIO Employees
REGENXBIO had 371 employees as of December 31, 2025. The number of employees increased by 18 or 5.10% compared to the previous year.
Employees
371
Change (1Y)
18
Growth (1Y)
5.10%
Revenue / Employee
$236,717
Profits / Employee
-$781,704
Market Cap
355.16M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 371 | 18 | 5.10% |
| Dec 31, 2024 | 353 | 9 | 2.62% |
| Dec 31, 2023 | 344 | -57 | -14.21% |
| Dec 31, 2022 | 401 | 29 | 7.80% |
| Dec 31, 2021 | 372 | 66 | 21.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Puma Biotechnology | 179 |
| Verastem | 102 |
| Editas Medicine | 87 |
| Larimar Therapeutics | 71 |
| Lexeo Therapeutics | 59 |
| Atea Pharmaceuticals | 55 |
| X4 Pharmaceuticals | 45 |
RGNX News
- 11 days ago - Regenxbio price target lowered to $26 from $30 at H.C. Wainwright - TheFly
- 27 days ago - REGENXBIO Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 4 weeks ago - Regenxbio price target lowered to $16 from $17 at Morgan Stanley - TheFly
- 4 weeks ago - Regenxbio price target lowered to $14 from $25 at BofA - TheFly
- 4 weeks ago - Regenxbio price target lowered to $12 from $37 at Barclays - TheFly
- 4 weeks ago - REGENXBIO Earnings release: Q1 2026 - Filings
- 4 weeks ago - REGENXBIO Quarterly report: Q1 2026 - Filings